Palvella Therapeutics (PVLA) Cash from Operations Growth (5y) (2018 - 2026)
Palvella Therapeutics (PVLA) Cash from Operations Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Palvella Therapeutics | 1.88 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.13% |
| Dec 31, 2025 | 18.23% |
| Sep 30, 2025 | -0.86% |
| Jun 30, 2025 | 11.09% |
| Mar 31, 2025 | 14.86% |
| Dec 31, 2024 | 17.34% |
| Sep 30, 2024 | 26.35% |
| Jun 30, 2024 | 31.63% |
| Mar 31, 2024 | 40.76% |
| Dec 31, 2023 | 33.61% |
| Sep 30, 2023 | 7.50% |
| Jun 30, 2023 | -8.37% |
| Mar 31, 2023 | -18.64% |
| Dec 31, 2022 | -22.47% |
| Sep 30, 2022 | -17.60% |
| Jun 30, 2022 | -19.02% |
| Mar 31, 2022 | -23.55% |
| Dec 31, 2021 | -10.22% |
| Sep 30, 2021 | -32.29% |
| Jun 30, 2021 | 47.13% |